Siemens Healthineers has inked a data-sharing deal with Blue Earth Diagnostics for access to anonymized radiohybrid prostate-specific membrane antigen (PSMA) F-18 rhPSMA-7.3 clinical data and images.
In an agreement with Blue Earth and the University Hospital of Technical University of Munich (TUM), Siemens plans to evaluate the data to enhance its analytics and artificial intelligence-based algorithms for prostate cancer for its PET/CT imaging software.
F-18 rhPSMA-7.3 is a radiotracer synthesized by researchers at TUM, and it is being developed by Blue Earth. The tracer is currently being studied in two multicenter phase III trials, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
